drugset / Trial / NCT04246359
Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
A phase 2 open label study to evaluate safety and activity of Rituximab(HLX01) in combination with Pegylated interferon α-2b in patients with newly diagnosed advanced indolent B-cell lymphoma.
Timeline
- Start
- 2020-01-15
- Primary completion
- 2022-06-16
- Completion
- 2023-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 135 ug | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |